VitaSpring Biomedical Co., Ltd. filed its Form 10-Q for the quarterly period ended April 30, 2026. The company reported no revenue for the quarter, consistent with the prior year's period. Operating expenses increased to $75,844 from $69,147 in the same period last year, primarily due to higher professional fees and stable salaries. The net loss for the quarter was $75,844, a slight improvement from $80,541 in the prior year's quarter. The company has a significant working capital deficit of $4,508,072 as of April 30, 2026. Substantial doubt exists regarding the company's ability to continue as a going concern within one year due to its limited cash, recurring losses, and significant liabilities. Management plans to seek additional capital through equity financing, strategic partnerships, and related-party support. A material weakness in internal control over financial reporting was identified due to inadequate segregation of duties and insufficient accounting personnel with U.S. GAAP and SEC reporting expertise.